Regulatory Open Forum

 View Only
  • 1.  Change in OS - Special or Traditional 510(k)

    Posted 24-Jun-2014 02:05
    Situation: Medical SW runs on a standard cell phone. The OS (Operating System) of the cell phone is Windows Mobile. A new cell phone is now used for the medical SW, and the phone has an Android OS.

    FDA says that a Letter to File cannot be used when there is a change to the "operating principle."
    A change to the OS is not a change to the operating principle, but is a major SW change, which will probably require a new 510(k).

    Question: is a Special 510(k) appropriate for such a change (to the OS); of course, the intended use, etc. remain the same and all the other conditions for a Special 510(k) are fulfilled.

    -------------------------------------------
    Asher Kassel
    Lifewatch Technologies Ltd.
    Rehovot
    Israel
    -------------------------------------------


  • 2.  RE: Change in OS - Special or Traditional 510(k)

    Posted 25-Jun-2014 08:35
    Hi Asher,

    A Special 510(k) would be required as the change in the OS does not affect the intended use of the device nor alter the fundamental scientific technology of the device.

    -------------------------------------------
    Lori Kahler
    Director Regulatory and Compliance
    Samsung Electronics America, Inc.
    Ridgefield Park NJ
    United States
    -------------------------------------------




  • 3.  RE: Change in OS - Special or Traditional 510(k)

    Posted 25-Jun-2014 09:31
    This is covered in the K97-1 Memorandum (still active), Deciding When to Submit a 510(k) for a Change to an txiating Device​, under Technology Engineering, and Performance Changes, B8, starting on p14.  Based on what I've seen in the past, I believe this would be a Traditional.  Should you choose to submit as a Special, there may be a high likelihood of coversion to a Traditional, which may slow the clock down.  Depending on where you are in the development process, you may always ask FDA via a pre-submission meeting teleconference (reference thr following Guidance Document: The Pre-Submission Program and Meetings with Food and Drug Administration Staff).  

    -------------------------------------------
    Julia Nelson RAC
    Principal Regulatory Affairs Specialist
    Medtronic Cardiovascular
    Moundsview MN
    United States
    -------------------------------------------